Passavanti MB, et al. - The therapeutic efficacy of ultramicronized palmitoylethanolamide (um-PEA) as add-on therapy to tapentadol (TP) was compared with that of TP therapy only in patients suffering from chronic low back pain (LBP). Findings indicated that when given as an add-on to TP, um-PEA may afford an innovative therapeutic intervention for the management of chronic LBP with a neuropathic component, as well as to improve patient quality of life. Moreover, without exerting any serious side effects, this combination treatment allowed a reduction in TP dose over time.